Shanghai unit to buy remaining 15% stake of STA Pharmaceutical to improve efficiency of active drug ingredient business, company says

WuXi AppTec’s Hong Kong debut will follow its blockbuster Shanghai listing earlier this year

WuXi AppTec’s plan would make it first in new generation of private biotech firms with dual listings

Hot drugmaker’s decision follows mainland IPO that saw its stock rise more than sixfold at one point